David Kirn, 4D Molecular Therapeutics CEO
January 10, 2023 12:49 PM ESTUpdated January 11, 07:57 AM
R&D
Cell/Gene Tx

4D Mol­e­c­u­lar paus­es en­roll­ment in Fab­ry tri­als af­ter kid­ney prob­lems in three pa­tients

Kyle LaHucik

Senior Reporter

4D Mol­e­c­u­lar Ther­a­peu­tics said it has stopped en­rolling pa­tients in its two clin­i­cal tri­als of a gene ther­a­py be­ing in­ves­ti­gat­ed for Fab­ry dis­ease.

The biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times